ÐÓ°ÉÔ­´´

Orikine Bio, based in Barcelona, stands out with its focus on cytokine-based therapies. Using a B2B business model, it targets advanced biological treatments, differentiating itself from conventional pharmaceutical approaches. This innovation could accelerate medical advancements and provide new treatment options where traditional methods have stalled. Backed by investors like AdBio Partners and Asabys Partners, Orikine Bio is well-positioned to leverage its proprietary technologies for significant strides in health care, offering competitive advantages and growth prospects.